IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Grimes & Company Inc.

Grimes & Company Inc. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,641 shares of the company’s stock after selling 58 shares during the quarter. Grimes & Company Inc.’s holdings in IDEXX Laboratories were worth $2,506,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Valley National Advisers Inc. boosted its holdings in shares of IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares in the last quarter. Riverview Trust Co purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at about $26,000. Geo Capital Gestora de Recursos Ltd purchased a new stake in IDEXX Laboratories during the third quarter worth about $28,000. Covestor Ltd boosted its holdings in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after buying an additional 28 shares in the last quarter. Finally, DSM Capital Partners LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 1.4 %

Shares of NASDAQ IDXX opened at $487.20 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a market capitalization of $40.24 billion, a PE ratio of 47.16, a price-to-earnings-growth ratio of 3.97 and a beta of 1.33. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The firm’s 50-day moving average is $501.58 and its two-hundred day moving average is $526.81.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.13. The company had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research analyst reports. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Finally, Barclays decreased their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $586.63.

Insider Activity

In other news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.